Latest Breaking News On - Epimab biotherapeutics inc - Page 1 : comparemela.com

EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting

EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEpimab biotherapeuticsYuan wangJason tangKaren sharmaChengbin wuSociety for immunotherapy of cancerEpimab biotherapeutics incAnnual meetingPhasei studyRefractory multiple myelomaFabs in tandem immunoglobulinMonovalent asymmetric tandem fab

EpimAb Biotherapeutics Announces U S FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

EpimAb Biotherapeutics Announces U S FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jason tangDavid guChengbin wuEpimab biotherapeuticsYuan wangStephan lenskyEmily wongDrug administrationEpimab biotherapeutics incWall streetInvestigational new drugBin pengFabs in tandem immunoglobulin

EpimAb Biotherapeutics Announces U S FDA Clearance of IND Application for Phase Ib/II Trial of EMB-

SHANGHAI & SUZHOU, China (BUSINESS WIRE) EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients wi.

Jason tangDavid guChengbin wuEpimab biotherapeuticsYuan wangStephan lenskyEmily wongDrug administrationEpimab biotherapeutics incInvestigational new drugBin pengFabs in tandem immunoglobulin

EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X Zhu

SHANGHAI & SUZHOU, China (BUSINESS WIRE) EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Zhu is internationally recognized as a leading authority in hepatoc.

United statesJason tangAndrewx zhuMario brkuljDavid guChengbin wuEpimab biotherapeuticsStephan lenskyHospital cancer centerProfessor of medicine at harvard medical schoolJiahui healthColumbia universityInternational liver cancer associationAmerican college of physiciansV foundation for cancer researchEpimab biotherapeutics inc

EpimAb Biotherapeutics Appoints Jerry Su, Ph D as Chief Technology Officer

EpimAb Biotherapeutics Appoints Jerry Su, Ph D as Chief Technology Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJason tangDavid guChengbin wuEpimab biotherapeuticsJerry suStephan lenskyEmily wongUniversity of chemical technologyZhejiang huahai biopharmaceuticals coVirginia universityTianjin universityEpimab biotherapeutics incChief technology officerSuzhou biobayZhejiang huahai biopharmaceuticals